Guidelines 1 COVID retningslinje (2024 version 29)
Ændringer siden version 28: Moderat risikogruppe udgår. Gravide udgår som risikogruppe. Skærpelse af kriterier for opstart af Paxlovid (nu kun højrisiko patient med indikation). 2 Antivirale midler til SARS-CoV-2 (2022)
Vurdering af behov for antivirale midler og effekt af SARS-CoV2 infektion i de risikogrupper, som ifølge gældende retningslinjer skal tilbydes behandling med lægemidlet. Værktøj 1 Aktuelle tal (SSI)
2 Aktuelle tal (ECDC)
3 Aktuelle tal (WHO)
4 Aktuelle tal (Johns Hopkins University)
5 Mortalitetsmonitorering (EuroMOMO)
6 Genomic epidemiology of SARS-CoV-2 (Nextstrain)
7 Liverpool COVID-19 drug interactions
8 Standford Coronavirus antiviral & resistance database
Links 1 SSI's epidemiologiske rapporter med særligt fokus på udvalgte perspektiver af COVID-19 udbruddet
2 Sundhedsstyrelsens side om COVID-19
3 Sundhedsstyrelsens retningslinjer for håndtering af COVID-19
4 Sundhedsstyrelsens COVID-19: Risikovurdering, strategi og tiltag ved epidemi i Danmark
5 Sundhedsstyrelsens vejledning: Personer med øget risiko for alvorligt COVID-19 sygdomsforløb
6 Sundhedsstyrelsens Nationale Kliniske Anbefaling: Brug af lægemidler ved forebyggelse og behandling af COVID-19
7 Dansk Selskab for Infektionsmedicins dokument: Patienter med øget risiko for et alvorligt COVID-19 sygdomsforløb
Nye artikler 1 Moral distress related to paid and unpaid care among healthcare workers during the COVID-19 pandemic
Julia Smith, Muhammad Haaris Tiwana, Alice Murage, Hasina Samji, Rosemary Morgan, Jorge Andres Delgado-Ron PLoS One Infectious Diseases, 10.09.2024 Tilføjet 10.09.2024 by Julia Smith, Muhammad Haaris Tiwana, Alice Murage, Hasina Samji, Rosemary Morgan, Jorge Andres Delgado-Ron While there is growing literature on experiences of healthcare workers and those providing unpaid care during COVID-19, little research considers the relationships between paid and unpaid care burdens and contributions. We administered a moral distress survey to healthcare workers in Canada, in 2022, collecting data on both paid and unpaid care. There were no significant differences in the proportion of participants providing unpaid care by gender, with both genders equally affected by certain responsibilities such as reduced contact with family/loved ones. However, men were significantly more distressed about specific unpaid care responsibilities. Unpaid care was not significantly associated with differences in intention to leave work. At work, women were significantly more concerned about patients unable to see family, while men were distressed by others mistreating COVID patients. This study enhances understanding of paid and unpaid care relationships, particularly during crises, and proposes an innovative method for assessing unpaid care burdens. Læs mere Tjek på PubMed2 Co-infections and secondary infections amid COVID-19 outbreaks in Vietnam
BMC Infectious Diseases, 10.09.2024 Tilføjet 10.09.2024 Abstract Background The mortality risk of co-infections/secondary infections (CoI/ScI) is under-reported in patients with non-critical COVID-19, leading to the under-management of CoI/ScI and publication bias in the medical literature. We aimed to investigate the association between CoI/ScI and mortality in patients hospitalised with mild-to-severe COVID-19. Methods We conducted a retrospective cohort study at a COVID-19 treatment hospital in Vietnam and collected all eligible medical records, with CoI/ScI status as the exposure (non-CoI/ScI and CoI/ScI, with the latter including nature of pathogen [bacterial, fungal, or bacterial + fungal] and multidrug-resistance pathogen [no MDRp or ≥ 1 MDRp]). The outcome was all-cause mortality, defined as in-hospital death by all causes or being discharged under critical illness. We used time-dependent analysis to report rates of mortality with 95% confidence intervals (95% CI, Poisson regression) and hazard ratios (HR) with 95% CI (Cox proportional hazards regression with Holm’s method for multiplicity control). Results We followed 1466 patients (median age 61, 56.4% being female) for a median of 9 days. We recorded 387 (26.4%) deaths (95/144 [66.0%] in the CoI/ScI group and 292/1322 [22.1%] in the non-CoI/ScI group). Adjusted mortality rates (per 100 person-days) of the CoI/ScI (6.4, 95% CI 5.3 to 7.8), including bacterial (8.0, 95% CI 7.2 to 8.9), no MDRp (5.9, 95% CI 4.8 to 7.4), and ≥ 1 MDRp (9.0, 95% CI 8.2 to 10.0) groups were higher than that of the non-CoI/ScI group (2.0, 95% CI 1.8 to 2.2). These corresponded to higher risks of mortality in the overall CoI/ScI (HR 3.27, 95% CI 2.58 to 4.13, adjusted p Læs mere Tjek på PubMed3 Investigating the relationship between lymphocyte cells apoptosis and DNA damage and oxidative stress and therapeutic and clinical outcomes of COVID-19 elderly patients
BMC Infectious Diseases, 10.09.2024 Tilføjet 10.09.2024 Abstract Background While COVID-19 has been controlled and deaths have decreased, the long-term consequences of COVID-19 remain a challenge we face today. This study was conducted to determine the relationship between the apoptosis of lymphocyte cells with DNA damage and oxidative stress and the therapeutic and clinical outcomes of elderly patients with COVID-19. Methods This study was conducted from April 2020 to May 2021 (the period of severe attacks of the epidemic peak of COVID-19) and September 2022 (the post-COVID-19 period). The study groups included elderly patients with COVID-19 hospitalized in the ICU and normal wards of the hospital as well as elderly patients with influenza. A polymerase chain reaction was used to check the validity of the studied diseases. The Annexin V/Propidium Iodide method was used to evaluate the level of apoptosis. Genotoxic effects and DNA damage were assessed by the comet assay method. Total antioxidant status (TAS), total oxidant status (TOS), and myeloperoxidase activity (MPO) were measured by photometric methods. Results The highest level of apoptosis in peripheral blood lymphocytes and the highest level of DNA damage were observed at both times in the intubated-ICU and non-intubated-ICU groups. In all groups, there was a significant increase in peripheral blood lymphocyte apoptosis levels and DNA damage levels compared to the healthy control group (p Læs mere Tjek på PubMed4 Comparing the immunogenicity of COVID-19 infection and vaccination in pregnant women as measured by anti-S IgG
BMC Infectious Diseases, 10.09.2024 Tilføjet 10.09.2024 Abstract Background Pregnancy is a critical time for women, making them more susceptible to infectious diseases like COVID-19. This study aims to determine the immunogenicity of COVID-19 in pregnant women who have been infected compared to those who have received the inactive COVID-19 vaccine. Materials and methods In this retrospective cohort study, pregnant women who received the inactivated COVID-19 vaccine (Sinopharm) and those with a history of COVID-19 infection during pregnancy were studied. Participants who had experienced stillbirth, received different COVID-19 vaccines, or had intrauterine fetal death were excluded from the study. Overall, the study included 140 participants. The participants were divided into two groups of 70 participants - pregnant women who received the Sinopharm vaccine and pregnant women who had COVID-19 infection during pregnancy. Before delivery, blood samples were collected from all mothers to evaluate the maternal immunoglobulin G (IgG) level. Blood samples were also taken from the baby’s umbilical cord during delivery to measure the newborn’s IgG level. Additionally, blood samples were collected from babies whose mothers showed signs of acute infection to measure their IgM levels and evaluate vertical transmission. Findings The study found a significant relationship between the mean level of maternal IgG and umbilical cord IgG within the groups (P Læs mere Tjek på PubMed5 [Articles] Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, Najib M Rahman, Duncan B Richards, Gail Hayward, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Haroon Ahmed, Andrew Carson-Stevens, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, May Ee Png, Mark Lown, Oliver van Hecke, Bhautesh D Jani, Nigel D Hart, Daniel Butler, Lucy Cureton, Meena Patil, Monique Andersson, Maria Coates, Clare Bateman, Jennifer C Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Ly-Mee Yu, F D Richard Hobbs, Paul Little, Christopher C Butler, PANORAMIC Trial Collaborative Group Lancet Infectious Diseases, 10.09.2024 Tilføjet 10.09.2024 In a vaccinated population, people treated with molnupiravir for acute COVID-19 felt better, experienced fewer and less severe COVID-19 associated symptoms, accessed health care less often, and took less time off work at 6 months. However, the absolute differences in this open-label design are small with high numbers needed to treat. Læs mere Tjek på PubMed6 Assessment of factors associated with self-medication practices during the COVID-19 pandemic in southwestern Ethiopia: a community-based cross-sectional survey
BMC Infectious Diseases, 7.09.2024 Tilføjet 7.09.2024 Abstract Background Self-medication practices involve the use of medications without healthcare professional requests. The threat of coronavirus disease 2019 (COVID-19) caused the practice of a fittest to survive action, with the assumption that something is better than nothing. Moreover, owing to the lack of effective treatment for COVID-19, the general public has shifted toward self-medication and symptomatic treatment, with approximately 80% of people stockpiling medication for use during the pandemic. Thus, this study aimed to assess the factors associated with self-medication practices during the COVID-19 pandemic crisis in southwestern Ethiopia. Methods A community-based cross-sectional study design was employed at selected drug retail outlets in southwestern Ethiopia for 415 community pharmacy clients from July 1, 2021, to September 1, 2021. Purposive sampling techniques were employed to select five drug retail outlets on the basis of high patient flows, and we took the study participants until the required quota allotted to each selected drug retail outlet had been filled. Bivariable and multivariable logistic regression analyses were employed to identify factors associated with self-medication. AORs with 95% CIs were used to report associations, and the level of significance was set at P Læs mere Tjek på PubMed7 Correction: Severe COVID-19 infection: An institutional review and literature overview
The PLOS ONE Editors PLoS One Infectious Diseases, 7.09.2024 Tilføjet 7.09.2024 8 Association between FTO polymorphism and COVID-19 mortality among older adults: a population-based cohort study
Jaroslav A. Hubacek, Nadezda Capkova, Martin Bobak, Hynek Pikhart International Journal of Infectious Diseases, 6.09.2024 Tilføjet 6.09.2024 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused global pandemic of COVID-19 disease with nearly 775 million cases and 7 million cumulative deaths worldwide. The Czech Republic was among countries most affected [1], with more than 4.5 mil confirmed cumulative cases and almost 43,500 deaths. (//covid19.who.int, accessed March 07, 2024). Læs mere Tjek på PubMed9 Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Journal of Infectious Diseases, 6.09.2024 Tilføjet 6.09.2024 Abstract Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38–4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44–2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, −.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, −.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated.Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802. Læs mere Tjek på PubMed10 Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study
BMC Infectious Diseases, 5.09.2024 Tilføjet 5.09.2024 Abstract Background During the pandemic period, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutated, leading to changes in the disease’s severity and the therapeutic effect of drugs accordingly. This study aimed to present the actual use of therapeutics and clinical outcomes based on the prevalence of each variant using real-world data. Methods We analyzed the electronic medical records of adult patients admitted to Busan Medical Center after confirming coronavirus disease 2019 (COVID-19) from February 1, 2020, to June 30, 2022. Patients with mild-to-moderate COVID-19 who were at a high risk of disease progression were selected as study subjects, and the time period was classified according to the variants as ancestral strain, Delta variant, or Omicron variant. We compared drug use status and clinical outcomes by time period. Results Among all 3,091 patients, corticosteroids were the most commonly used therapy (56.0%), being used most frequently in the Delta variant (93.0%), followed by the Omicron variant (42.9%) and ancestral strain (21.2%). Regdanvimab accounted for the majority of therapeutic use in the Delta variant (82.9%) and ancestral strain (76.8%), whereas remdesivir was most frequently used during the Omicron variant period (68.9%). The composite outcomes of death or disease aggravation were ranked in the order of the Delta variant, Omicron variant, and ancestral strain (14.5, 11.9, and 6.0%, respectively, P Læs mere Tjek på PubMed11 Decreased hospital-acquired respiratory infections among older inpatients during the COVID-19 pandemic: a retrospective observational study in a general hospital in China
BMC Infectious Diseases, 5.09.2024 Tilføjet 5.09.2024 Abstract Background To mitigate hospital-acquired transmission of coronavirus disease 2019 (COVID-19), various prevention and control measures have been strictly implemented in medical institutions. These stringent measures can potentially reduce the incidence of hospital-acquired respiratory infections. This study aimed to assess if there were changes in the prevalence of hospital-acquired respiratory infections during a period of national attention focused on COVID-19 prevention. Methods A retrospective analysis of the clinical data from adult patients with hospital-acquired respiratory infections admitted between October and December 2019 and during the same period in 2020 was performed. All patients were referred from a general hospital in Beijing China and COVID-19 patients were not treated at the hospital. Hospital-acquired respiratory infections were diagnosed based on the criteria of the Centers for Disease Control and Prevention/National Healthcare Safety Network (CDC/NHSN). A comparison of the incidence and mortality rate of hospital-acquired respiratory infections between the two selected time periods was conducted. Additionally, multivariate logistics regression analysis was used to identify mortality-associated risk factors. Results This study included 2,211 patients from October to December 2019 (pre-COVID-19 pandemic) and 2,921 patients from October to December 2020 (during the COVID-19 pandemic). The incidence of hospital-acquired respiratory infections in 2019 and 2020 was 4.7% and 2.9%, respectively, with odds ratio (OR): 0.61, 95% confidence interval (CI): 0.46–0.81, and P = 0.001. In-hospital mortality of hospital-acquired respiratory infections in 2019 and 2020 was 30.5% and 38.4%, respectively, with OR: 1.42, 95%CI: 0.78–2.59, and P = 0.25. Multivariate logistics regression analysis revealed that a history of previous malignancy (OR: 2.50, 95%CI: 1.16–5.35, P = 0.02), was associated with in-hospital mortality. Conclusions The incidence of hospital-acquired respiratory infections was significantly decreased following the implementation of various prevention and control measures during the COVID-19 pandemic. A history of previous malignancy was associated with higher in-hospital mortality in older inpatients with hospital-acquired respiratory infections. Læs mere Tjek på PubMed12 COVID-19 in the Tibet, China, the roof of the world: a comparative analysis of high-altitude residents and newcomers
BMC Infectious Diseases, 5.09.2024 Tilføjet 5.09.2024 Abstract Background After a 920-day hiatus, COVID-19 resurged in the Tibet Autonomous Region of China in August 2022. This study compares the characteristics of COVID-19 between high-altitude residents and newcomers, as well as between newcomers and lowlanders. Methods This multi-center cohort study conducted at the Third People’s Hospital of Tibet Autonomous Region and Beijing University Shenzhen Hospital, included 520 high-altitude resident patients, 53 high-altitude newcomer patients, and 265 lowlander patients infected with the Omicron variant. Initially, we documented epidemiological, clinical, and treatment data across varying residency at admission. We compared the severity of COVID-19 and various laboratory indicators, including hemoglobin concentration and SpO2%, over a 14-day period from the date of the first positive nucleic acid test, as well as the differences in treatment methods and disease outcomes between highlanders and high-altitude newcomers. We also compared several characteristics of COVID-19 between high-altitude newcomers and lowlanders. Univariate analysis, multivariable logistic regression, and the generalized linear mixed model were utilized for the analysis. Results No fatalities were observed. The study found no significant differences in COVID-19 severity or in the physiological measures of hemoglobin concentration and SpO2% between high-altitude and lowland residents. Similarly, there were no statistically significant differences in the values or trends of hemoglobin and SpO2% between high-altitude residents and newcomers throughout the 14-day observation period. However, compared to age- and sex-matched lowlander patients (1:5 ratio), high-altitude newcomers exhibited higher heart rates, respiratory rates, and average hemoglobin concentrations, along with lower platelet counts. There were no significant differences in hospital stays between the two groups. Conclusions High-altitude residents and newcomer patients exhibit clinical similarities. However, the clinical characteristics of high-altitude newcomers and lowlander patients differ due to the impact of the high-altitude environment. These results highlight potential considerations for public health strategies in high-altitude regions such as Tibet. Læs mere Tjek på PubMed13 The mediation effects of COVID-19-related traumatic stress symptoms and mentalization on the relationship between perceived stress and psychological well-being in healthcare workers transitioning to a post-pandemic world
Qian Wang, You Zhou, Gang Wang, Xinyu Pan, Sha Sha, Zhe Wang, Yinqi Liu, Tengfei Tian, Sixiang Liang PLoS One Infectious Diseases, 5.09.2024 Tilføjet 5.09.2024 by Qian Wang, You Zhou, Gang Wang, Xinyu Pan, Sha Sha, Zhe Wang, Yinqi Liu, Tengfei Tian, Sixiang Liang Background In context of COVID-19 as a collective trauma and the intense involvement of healthcare workers (HCWs) in the pandemic, perceived stress continues to have a tremendous impact on their psychological well-being. However, few studies have attempted to delineate the underlying mechanisms. This study examined whether COVID-19-related traumatic stress symptoms and mentalization act as mediators. Methods A sample of HCWs (N = 2610) from 22 hospitals in Beijing, China participated in this cross-sectional investigation. Data on their perceived stress, psychological well-being, the impact of event, and reflective function during the COVID-19 pandemic were collected using self-report questionnaires. Different mediating models were tested. Results COVID-19-related stress symptoms and mentalization independently mediate the association between perceived stress and psychological well-being. These two mediators also compose a serial mediation model. In particular, higher perceived stress inhibits the psychological well-being of HCWs through increased severity of traumatic stress symptoms, which in turn is associated with hypomentalizing. Conclusion These findings shed light on the mechanisms underlying the relationship between perceived stress and psychological well-being in HCWs. We strongly recommend incorporating a mentalization framework with trauma-informed practice in prevention and intervention work with this population during this and future healthcare crisis. Læs mere Tjek på PubMed14 Salivary immune responses after COVID-19 vaccination
Kenny Nguyen, Boris Relja, Monica Epperson, So Hee Park, Natalie J. Thornburg, Veronica P. Costantini, Jan Vinjé PLoS One Infectious Diseases, 4.09.2024 Tilføjet 4.09.2024 by Kenny Nguyen, Boris Relja, Monica Epperson, So Hee Park, Natalie J. Thornburg, Veronica P. Costantini, Jan Vinjé mRNA-based COVID-19 vaccines have played a critical role in reducing severe outcomes of COVID-19. Humoral immune responses against SARS-CoV-2 after vaccination have been extensively studied in blood; however, limited information is available on the presence and duration of SARS-CoV-2 specific antibodies in saliva and other mucosal fluids. Saliva offers a non-invasive sampling method that may also provide a better understanding of mucosal immunity at sites where the virus enters the body. Our objective was to evaluate the salivary immune response after vaccination with the COVID-19 Moderna mRNA-1273 vaccine. Two hundred three staff members of the U.S. Centers for Disease Control and Prevention were enrolled prior to receiving their first dose of the mRNA-1273 vaccine. Participants were asked to self-collect 6 saliva specimens at days 0 (prior to first dose), 14, 28 (prior to second dose), 42, and 56 using a SalivaBio saliva collection device. Saliva specimens were tested for anti-spike protein SARS-CoV-2 specific IgA and IgG enzyme immunoassays. Overall, SARS-CoV-2-specific salivary IgA titers peaked 2 weeks after each vaccine dose, followed by a sharp decrease during the following weeks. In contrast to IgA titers, IgG antibody titers increased substantially 2 weeks after the first vaccine dose, peaked 2 weeks after the second dose and persisted at an elevated level until at least 8 weeks after the first vaccine dose. Additionally, no significant differences in IgA/IgG titers were observed based on age, sex, or race/ethnicity. All participants mounted salivary IgA and IgG immune responses against SARS-CoV-2 after receiving the mRNA-1273 COVID-19 vaccine. Because of the limited follow-up time for this study, more data are needed to assess the antibody levels beyond 2 months after the first dose. Our results confirm the potential utility of saliva in assessing immune responses elicited by immunization and possibly by infection. Læs mere Tjek på PubMed15 COVID-19 Increased Existing Gender Mortality Gaps in High Income More than Middle Income Countries
Kathleen Beegle, Gabriel Demombynes, Damien de Walque, Paul Gubbins, Jeremy Veillard International Journal of Infectious Diseases, 3.09.2024 Tilføjet 3.09.2024 In all1 countries around the world, women live longer than men [1,2]. There is well-established evidence of a gender mortality gap driven by a range of environmental, genetic, and cultural factors [3]. The persistence of higher mortality for men than women has been documented with data typically drawn principally from high-income countries [4]. But these patterns have also been shown in low-income regions of the world [5]. Læs mere Tjek på PubMed16 Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study
BMC Infectious Diseases, 3.09.2024 Tilføjet 3.09.2024 Abstract Background During the pandemic period, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutated, leading to changes in the disease’s severity and the therapeutic effect of drugs accordingly. This study aimed to present the actual use of therapeutics and clinical outcomes based on the prevalence of each variant using real-world data. Methods We analyzed the electronic medical records of adult patients admitted to Busan Medical Center after confirming coronavirus disease 2019 (COVID-19) from February 1, 2020, to June 30, 2022. Patients with mild-to-moderate COVID-19 who were at a high risk of disease progression were selected as study subjects, and the time period was classified according to the variants as ancestral strain, Delta variant, or Omicron variant. We compared drug use status and clinical outcomes by time period. Results Among all 3,091 patients, corticosteroids were the most commonly used therapy (56.0%), being used most frequently in the Delta variant (93.0%), followed by the Omicron variant (42.9%) and ancestral strain (21.2%). Regdanvimab accounted for the majority of therapeutic use in the Delta variant (82.9%) and ancestral strain (76.8%), whereas remdesivir was most frequently used during the Omicron variant period (68.9%). The composite outcomes of death or disease aggravation were ranked in the order of the Delta variant, Omicron variant, and ancestral strain (14.5, 11.9, and 6.0%, respectively, P Læs mere Tjek på PubMed17 Decreased hospital-acquired respiratory infections among older inpatients during the COVID-19 pandemic: a retrospective observational study in a general hospital in China
BMC Infectious Diseases, 3.09.2024 Tilføjet 3.09.2024 Abstract Background To mitigate hospital-acquired transmission of coronavirus disease 2019 (COVID-19), various prevention and control measures have been strictly implemented in medical institutions. These stringent measures can potentially reduce the incidence of hospital-acquired respiratory infections. This study aimed to assess if there were changes in the prevalence of hospital-acquired respiratory infections during a period of national attention focused on COVID-19 prevention. Methods A retrospective analysis of the clinical data from adult patients with hospital-acquired respiratory infections admitted between October and December 2019 and during the same period in 2020 was performed. All patients were referred from a general hospital in Beijing China and COVID-19 patients were not treated at the hospital. Hospital-acquired respiratory infections were diagnosed based on the criteria of the Centers for Disease Control and Prevention/National Healthcare Safety Network (CDC/NHSN). A comparison of the incidence and mortality rate of hospital-acquired respiratory infections between the two selected time periods was conducted. Additionally, multivariate logistics regression analysis was used to identify mortality-associated risk factors. Results This study included 2,211 patients from October to December 2019 (pre-COVID-19 pandemic) and 2,921 patients from October to December 2020 (during the COVID-19 pandemic). The incidence of hospital-acquired respiratory infections in 2019 and 2020 was 4.7% and 2.9%, respectively, with odds ratio (OR): 0.61, 95% confidence interval (CI): 0.46–0.81, and P = 0.001. In-hospital mortality of hospital-acquired respiratory infections in 2019 and 2020 was 30.5% and 38.4%, respectively, with OR: 1.42, 95%CI: 0.78–2.59, and P = 0.25. Multivariate logistics regression analysis revealed that a history of previous malignancy (OR: 2.50, 95%CI: 1.16–5.35, P = 0.02), was associated with in-hospital mortality. Conclusions The incidence of hospital-acquired respiratory infections was significantly decreased following the implementation of various prevention and control measures during the COVID-19 pandemic. A history of previous malignancy was associated with higher in-hospital mortality in older inpatients with hospital-acquired respiratory infections. Læs mere Tjek på PubMed18 COVID-19 in the Tibet, China, the roof of the world: a comparative analysis of high-altitude residents and newcomers
BMC Infectious Diseases, 3.09.2024 Tilføjet 3.09.2024 Abstract Background After a 920-day hiatus, COVID-19 resurged in the Tibet Autonomous Region of China in August 2022. This study compares the characteristics of COVID-19 between high-altitude residents and newcomers, as well as between newcomers and lowlanders. Methods This multi-center cohort study conducted at the Third People’s Hospital of Tibet Autonomous Region and Beijing University Shenzhen Hospital, included 520 high-altitude resident patients, 53 high-altitude newcomer patients, and 265 lowlander patients infected with the Omicron variant. Initially, we documented epidemiological, clinical, and treatment data across varying residency at admission. We compared the severity of COVID-19 and various laboratory indicators, including hemoglobin concentration and SpO2%, over a 14-day period from the date of the first positive nucleic acid test, as well as the differences in treatment methods and disease outcomes between highlanders and high-altitude newcomers. We also compared several characteristics of COVID-19 between high-altitude newcomers and lowlanders. Univariate analysis, multivariable logistic regression, and the generalized linear mixed model were utilized for the analysis. Results No fatalities were observed. The study found no significant differences in COVID-19 severity or in the physiological measures of hemoglobin concentration and SpO2% between high-altitude and lowland residents. Similarly, there were no statistically significant differences in the values or trends of hemoglobin and SpO2% between high-altitude residents and newcomers throughout the 14-day observation period. However, compared to age- and sex-matched lowlander patients (1:5 ratio), high-altitude newcomers exhibited higher heart rates, respiratory rates, and average hemoglobin concentrations, along with lower platelet counts. There were no significant differences in hospital stays between the two groups. Conclusions High-altitude residents and newcomer patients exhibit clinical similarities. However, the clinical characteristics of high-altitude newcomers and lowlander patients differ due to the impact of the high-altitude environment. These results highlight potential considerations for public health strategies in high-altitude regions such as Tibet. Læs mere Tjek på PubMed19 Clinical profiles and mortality predictors of hospitalized patients with COVID-19 in Ethiopia
BMC Infectious Diseases, 3.09.2024 Tilføjet 3.09.2024 Abstract Background Studying the characteristics of hospitalized Coronavirus Disease 2019 (COVID-19) patients is vital for understanding the disease and preparing for future outbreaks. The aim of this study was to analyze and describe the clinical profiles and factors associated with mortality among COVID-19 patients admitted to Jimma Medical Center COVID-19 Treatment Center (JMC CTC) in Ethiopia. Methods All confirmed COVID-19 patients admitted to JMC CTC between 17 April 2020 and 05 March 2022 were included in this study. Socio-demographic data, clinical information, and outcome variables were collected retrospectively from medical records and COVID-19 database at the hospital. Bivariable and multivariable analyses were performed to determine factors associated with COVID-19 severity and mortality. A P-value Læs mere Tjek på PubMed20 [Media Watch] Facing COVID-19 in South Africa
Jonathan Blott Lancet Infectious Diseases, 3.09.2024 Tilføjet 3.09.2024 At the onset of the pandemic, Glenda Gray, Lead Co-Investigator at Sisonke and President of the South African Medical Research Council, did something that she had not done in years: she stopped wearing her watch. March, 2020, marked the beginning of a societal standstill as restrictions to curb the spread of COVID-19 came into effect in South Africa and across the world. For Gray, time had paused. “Time will begin again when the pandemic is over”, she reflects, quoting Bob Dylan: The times they are a-changing. Læs mere Tjek på PubMed |
København
Torsdag d. 12. september
Auditorium C114-101, Aarhus University Hospital (Entrance C)
Torsdag d. 12. september
Masterclass Autoimmun Encephalitis 2024
Syddansk Universitet, Odense
Mandag d. 16. september
European Society for Clinical Virology (ESCV) 2024
Frankfurt, Tyskland
Onsdag d. 18. september
International Congress for Tropical Medicine and Malaria (ICTMM) 2024
Kuching, Sarawak, Malaysia
Torsdag d. 19. september
COVID retningslinje (2024 version 29)
Tilføjet 19. juli 2024
Tilføjet 1. juli 2024
Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)
Tilføjet 9. januar 2024
Antiretroviral behandling af HIV-smittede personer (2024)
Tilføjet 9. januar 2024
Vejledning til udformning af guidelines for dansk selskab for infektionsmedicin (2024)
Tilføjet 5. januar 2024
Virulence
Tilføjet 11. september 2024
Proceedings of the National Academy of Sciences
Tilføjet 11. september 2024
Nat Rev Microbiol
Tilføjet 11. september 2024
FEMS Microbiology Reviews
Tilføjet 11. september 2024
Emerg Microbes Infect
Tilføjet 10. september 2024
Cow's Milk Containing Avian Influenza A(H5N1) Virus - Heat Inactivation and Infectivity in Mice.
Udvalgt og kommenteret af Professor Lars Østergaard
Tilføjet 9. juni 2024
Udvalgt og kommenteret af Professor Troels Lillebæk
Tilføjet 29. november 2023
Hydrocortisone in Severe Community-Acquired Pneumonia.
Udvalgt og kommenteret af Professor Lars Østergaard
Tilføjet 27. september 2023
Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
Udvalgt og kommenteret af Professor Niels Obel
Tilføjet 27. september 2023
Udvalgt og kommenteret af Professor Troels Lillebæk
Tilføjet 22. september 2023
COVID retningslinje (2024 version 29)
Uploadet 19. juli 2024
Akut bakteriel meningitis (2018)
Uploadet 12. maj 2021
Borrelia klaringsrapport (2014)
Uploadet 12. maj 2021
Uploadet 13. maj 2021
Guidelines for diagnostik og behandling af spondylodiskitis (2018)
Uploadet 12. maj 2021